Gerium Medical Ltd.

www.geriumltd.com

Now Mennen Medical

High-Tech Company

Acquired by Redworth Capital Group

Graduated from: Abital

TECH VERTICALS

Babies, Blood, Diagnostics, Digital Health, Healthtech, Hospitals, Life Sciences, Medical Devices, MedTech, Spectroscopy

General Data

Sector	Medical Devices
Company Stage:	Initial Revenues
Established	2011
Number of Employees	7
Reg. Number:	abCDe

DESCRIPTION

Gerium Medical's mission is to develop state-of-the-art medical devices in the field of medical optics. Currently under development, Gerium Medical’s newest product, BiliCare, measures transcutaneous bilirubin in newborns using a non-invasive method. Future products will measure other substances from other parts of the human body.

TECHNOLOGY

Gerium Medical developed a non-invasive bilirubin meter for newborns called BiliCare™. The technology of the device is based on a field in physics called spectroscopy—measuring substances using light at varying wave lengths (visible or non-visible light). Gerium Medical's BiliCare measures the level of transcutaneous bilirubin in the newborn by transmitting light at different wave lengths through the newborn’s ear and measures the intensity of those wave lengths when they come out of the ear. The amount of light absorbed by the bilirubin is calculated by comparing the intensity of the light before it enters the tissue with its intensity after it leaves. Then the transcutaneous bilirubin of the newborn is calculated according to a customized algorithm.

Products and Phases

Product	Phase
BiliCare	Approved CE Approved AMAR
Neonatal Jaundice Diagnostics Device – Noninvasive Bilirubin Meter Gerium Medical’s BiliCare device reduces the number of “heel punctures” applied to neonates by measuring the level of transcutaneous bilirubin in a noninvasive manner. BiliCare measures the level of bilirubin using a patented technology developed by Gerium Medical’s engineers and scientists. Using light at different wave lengths and sophisticated measuring techniques, BiliCare measures the transcutaneous bilirubin levels in neonates.

	TARGET MARKETS
	Neonatology departments in hospitals and pediatric clinics.

	BUSINESS MODEL
	B2B

REMARKS

Date	Remark
01/06/2015	Following the acquisition by Redworth Capital Group, the company (IP and employees) was merged under Mennen Medical.

CONTACT INFO

Expand / Collapse All

Main Address: Yoqneam, Israel

Address	5 HaCarmel St., New industrial Park, Rakuto Kasei Building, Floor 3
POB	620
City	Yoqneam
Country	Israel
Zip	2060000

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Eyal Gerber	Co-Founder
Mr. Moshe Gerber	Co-Founder	IR-MED (CEO)

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Jun. 01, 2015

Initial Revenues

abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Second Round

Jan. 01, 2013

R&D

abCDe

First Round

Aug. 12, 2011

R&D

abCDe

Seed

Jun. 01, 2011

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Angel Club/ Group	abCDe
abC Defghij	Government Agency	abCDe	R&D Grant
abC Defghij	Incubator	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Jan. 01, 2011

Seed

Contributor	Type	Amount	Remarks
abC Defghij	Technology Transfer Company	abCDe

Last Updated:	abCDe
IVC Number:	abCDe